

PATIENT INFORMATION

Patient Name: _____ DOB: _____ Phone: _____ Sex: M / F Ht: _____ Wt: _____ lbs / kg
Primary Language: _____ Allergies: _____
Patient Preferred Location: _____

<ICD 10 CODE REQUIRED>

DIAGNOSIS & CLINICAL INFORMATION

ICD 10 Code

- | | |
|---|---|
| <input type="checkbox"/> L40.0 Psoriasis Vulgaris | <input type="checkbox"/> L40.8 Flexural Psoriasis |
| <input type="checkbox"/> L40.1 Generalized Pustular Psoriasis | <input type="checkbox"/> L40.9 Psoriasis, Unspecified |
| <input type="checkbox"/> L40.2 Acrodermatitis Continua | Other: _____ |
| <input type="checkbox"/> L40.3 Pustulosis Palmaris et Plantaris | |
| <input type="checkbox"/> L40.4 Guttate Psoriasis | |

REQUIRED: Demographics & Most Recent: H&P, clinical notes, & medication list. Supporting clinical notes to include any past tried and/or failed therapies, intolerance, outcomes, or contraindications to conventional therapy.
LAB RESULTS: Include Negative TB within 12 months.

PRESCRIPTION

Lab Orders+

Required: Negative TB, annually
+Medix Infusion will draw maintenance labs unless otherwise directed by Referring Provider.

Ilumya (tildrakizumab-asmn)

Loading Dose:

SubQ: Inject 100 mg at weeks 0 and 4

Maintenance Dose:

SubQ: Inject 100 mg every 12 weeks for one year

In the event of an adverse reaction occurring at a Medix Infusion suite, utilize the Medix Infusion adverse reaction protocol.

Post Treatment Observations: The patient is observed for 30 minutes following the first injection.

Comments: _____

PRESCRIBER INFORMATION

Prescriber Name: _____ *Signature:* _____
Date: _____ NPI #: _____ Specialty: _____
Supervising Physician: _____ (If Applicable)
Address: _____ City: _____ State: _____ Zip: _____
Contact Name: _____ Phone: _____ Fax: _____ Email: _____